Deprixol is used to treat depression. It is also used to treat general anxiety disorder, social anxiety disorder, and panic disorder. Deprixol belongs to a group of medicines known as serotonin and norepinephrine reuptake inhibitors (SNRI). These medicines are thought to work by increasing the activity of a chemical called serotonin in the brain.
Deprixol is available only with your doctor’s prescription.
Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Deprixol is used in certain patients with the following medical condition:
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol.
Deprixol (Deprixol hydrochloride) is indicated for the treatment of major depressive disorder.
The efficacy of Deprixol in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia.
A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation.
The efficacy of Deprixol in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Deprixol in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial. Nevertheless, the physician who elects to use Deprixol/Deprixol for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
Use Deprixol extended-release capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Ask your health care provider any questions you may have about how to use Deprixol extended-release capsules.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form.
Generalized anxiety disorder (extended-release capsules only): Treatment of generalized anxiety disorder (GAD)
Major depressive disorder (unipolar): Treatment of unipolar major depressive disorder (MDD)
Panic disorder (extended-release capsules only): Treatment of panic disorder, with or without agoraphobia
Social anxiety disorder (extended-release capsules and tablets only): Treatment of social anxiety disorder, also known as social phobia
Data from a limited number of small clinical trials suggest that Deprixol may be beneficial for the prevention of migraine.
Deprixol is formulated as an extended-release capsule for once-a-day oral administration. Drug release is controlled by diffusion through the coating membrane on the spheroids and is not pH dependent. Capsules contain Deprixol hydrochloride equivalent to 75 mg or 150 mg Deprixol.
Based on the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause, the Endocrine Society (ES) clinical practice guideline on the treatment of symptoms of menopause, and the North American Menopause Society (NAMS) position statement on nonhormonal management of menopause-associated vasomotor symptoms, SNRIs (including Deprixol) are an effective and recommended alternative for the management of vasomotor symptoms associated with menopause in patients with contraindications to hormonal therapy or who prefer not to use hormonal therapy. Based on the American Cancer Society (ACS)/American Society of Clinical Oncology (ASCO) breast cancer survivorship care guideline, SNRIs may be used to help mitigate vasomotor symptoms of premature menopause in women previously treated for breast cancer.
Deprixol hydrochloride is a structurally novel antidepressant for oral administration. It is designated (R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride or (±)-1-[α-[(dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol hydrochloride and has the empirical formula C17H27NO2HCl. Its molecular weight is 313.87.
Deprixol hydrochloride is a white to off-white crystalline solid with a solubility of 572 mg/mL in water (adjusted to ionic strength of 0.2 M with sodium chloride). Its octanol: Water (0.2 M sodium chloride) partition coefficient is 0.43.
Excipients/Inactive Ingredients: Microcrystalline cellulose, hydroxypropylmethylcellulose, ethylcellulose, gelatin, red and yellow iron oxides (E172), titanium dioxide (E171) and printing ink.
If you are not more worried about stomach pain, then you can withstand heavy loads at a new job, and the best vacancies can be found on this site – https://jobstellar.com/uk/